Status:
COMPLETED
Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Measles
Mumps
Eligibility:
All Genders
12-18 years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with...
Detailed Description
The duration of treatment is 6 weeks.
Eligibility Criteria
Inclusion
- Healthy children 12 to 18 months of age
Exclusion
- History or prior exposure to measles, mumps, or rubella
- History of allergic reactions to any component of the vaccines as evaluated by the study doctor
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
1210 Patients enrolled
Trial Details
Trial ID
NCT00092404
Start Date
December 1 2001
End Date
June 1 2005
Last Update
March 15 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.